PRESS RELEASE
18th September 2020

Download PDF

Mogrify wins Life Science Innovation Award and Prof. Julian Gough named Academic Entrepreneur of the Year at
Business Weekly Awards 2020

Mogrify recognized for furthering life science discovery for the benefit
of human healthcare through direct cellular conversion technology

Co-founder and CSO receives award celebrating his achievements in establishing Mogrify

Cambridge, UK, 18 September 2020: Mogrify Limited (Mogrify®), a UK company aiming to transform the development of ex vivo cell therapies and pioneer the field of in vivo reprogramming therapies, today announced it had won the AstraZeneca Life Science Innovation category of the Business Weekly Awards. The award commends Mogrify in applying its proprietary direct cellular conversion technology to further the cause of life science discovery for the benefit of human healthcare. Prof. Julian Gough, Co-founder and CSO of Mogrify, received the Cambridge Enterprise Academic Entrepreneur of the Year award in recognition of his work as a life science innovator and founder of Mogrify.

Mogrify’s proprietary direct cellular conversion technology determines the conversion factors required to convert (ex vivo or in vivo) any target cell type from any source cell type. The Company is deploying this platform to engineer an evergreen and scalable source of cell types that exhibit efficacy and safety profiles necessary to address diseases with a high unmet clinical need, such as in ophthalmological, immunological, hematological, and other disease areas.

Prof. Gough is a leading bioinformatician and biotech entrepreneur who led the development and application of the Mogrify platform, which utilizes a systematic big-data approach (Rackham et al., Nature Genetics, 2016) developed over a 10-year period via a multi-national research collaboration. Graduating with a PhD in molecular biology from the University of Cambridge, Julian became Professor of Bioinformatics at the University of Bristol and is now Programme Leader at the MRC Laboratory of Molecular Biology in Cambridge. He has also successfully started a number of biotech companies.

Dr. Darrin M. Disley, OBE, CEO, Mogrify, said: “Our team are committed to transforming healthcare for indications of high unmet clinical need. The award for Life Science Innovation attests to the potential of Mogrify’s platform and pioneering team to overcome safety, efficacy and scalability challenges for cell therapies and we are honored to have this recognized by the judges at this year’s esteemed business awards.

Julian is an outstanding scientist and entrepreneur who has worked tirelessly to advance Mogrify technology and drive its therapeutic application forward, paving the way for future treatments and inspiring those who work alongside him.”

Professor Julian Gough, Co-founder and CSO, Mogrify, said: “Following on from our previous success in the ‘Disruptive Technology’ category at last year’s Business Weekly Awards, I am delighted to see Mogrify go from strength to strength and achieve success again in 2020.

I am immensely proud to have been named ‘Academic Entrepreneur of the Year’ and would like to thank my peers who have supported me throughout my career and Mogrify’s talented team for their dedication and hard work in pioneering novel cell therapies.”

Since February 2019, Mogrify has raised over $20 million USD in seed and series A rounds and $2.5 million USD in grant funding, and has grown to a headcount over 60 of scientific, operational, and commercial staff.

For further information on Mogrify’s technology and leadership team, please visit:

https://mogrify.co.uk/cellular-conversion-technology/#our-science
https://mogrify.co.uk/leadership-team/#_leaders

Notes to Editors

Julian Gough, CSO

Prof. Julian Gough

Co-founder and CSO, Mogrify

Dr. Darrin M. Disley OBE - CEO

Dr. Darrin M. Disley, OBE

CEO, Mogrify

For high-resolution and alternate images please contact Zyme Communications

Mogrify Contacts
Darrin M. Disley, PhD, OBE
Tel: + 44 (0)1223 734154
Email: darrin@mogrify.co.uk

Zyme Communications (media inquiries)
Michelle Ricketts
Tel: +44 (0)7789 053 885
E-mail: michelle.ricketts@zymecommunications.com

Westwicke, an ICR Company (investor inquiries)
Stephanie Carrington
Tel: +1 (646) 277-1282
Email: stephanie.carrington@icrinc.com

About Mogrify www.mogrify.co.uk

Mogrify® has developed a proprietary direct cellular conversion technology that utilizes a systematic big-data approach (Rackham et al., Nature Genetics, 2016) developed over a 10-year period via a multi-national research collaboration. By deploying next-generation sequencing, gene regulatory and epigenetic network data, the platform enables the prediction of the transcription factors (or small molecules) and culture medium conditions required to produce (ex vivo or in vivo) any target cell type from any source cell type.

The platform can be used to enhance existing stem-cell forward reprogramming methods or can bypass development pathways altogether effecting a direct transdifferentiation between a mature cell type to another mature cell type.

Mogrify is applying its proprietary and award-winning platform to engineer an evergreen and scalable source of cell types that exhibit efficacy and safety profiles necessary to transform the development of cell therapies for indications of high unmet clinical need in hematological, immunological, ophthalmological and other disease areas.

Uniquely positioned to address a regenerative medicine market estimated to be worth $39 billion USD by 2023, Mogrify is commercializing its technology via a combination of internal cell and gene therapy development, co-development partnerships, and out-licensing of novel cell conversions. Based in Cambridge, UK, the Company has raised over $20 million USD funding from Ahren Innovation Capital, Parkwalk, 24Haymarket, Dr. Darrin M. Disley, OBE and the University of Bristol Enterprise Fund III.

Follow Mogrify on Twitter @Mogrify_UK and LinkedIn @Mogrify

Download PDF